Member Info for Matml74

Here are the thought from Harvard on this theory of comparing severity between populations and also the media trumpeting of ‘viruses always evolve to become milder’ rubbish.

“Viruses have no intrinsic tendency to evolve towards lower virulence; evolution simply selects those that excel at making more of themselves. In an illness like COVID-19 where the vast majority of spread occurs prior to severe disease, severity is likely not directly selected upon at all. HIV is a classic example of a successful pathogen despite being fatal in >99% of cases if untreated. Indeed, previously observed variants of SARS-CoV-2 with enhanced transmission (Alpha and Delta) appear to have greater intrinsic severity10-13. While the lower observed IFR in the early weeks of the Omicron wave in South Africa is better than the alternative, the most likely explanation lies in increased immunity among those being infected; more time and careful comparisons controlling for age, prior immunity, detection bias, lag period, hospital capacity, and numerous other factors will be required to infer anything about intrinsic virulence. Our collective intuition on how population-level IFR relates to intrinsic severity of a variant needs to be recalibrated over time as immunity accrues, and far more so with a variant as immune-evasive as Omicron.”

https://cdn1.sph.harvard.edu/wp-content/uploads/sites/2623/2021/12/21_Hanage_Bhattacharyya_Challenges-in-assessing-Omicron-severity_HCPDS-Working-Paper-Volume-21_No-10-1.pdf

...... But SNG don’t treat asymptomatic infections!

Drops below 10p its load up time.

Rosso, The 5% at FMV is for the havieron asset not the company. Your calcs are all wrong. What the GGP share price (mcap) is irrelevant to what is being valued (ie the gold/copper at Havieron) in the 5% option to NCM.

Fruits, just in relation to your points about bronchial infection it pays to remember the following wrt SNG001.

It is a fact that bronchial infection makes the lung more vulnerable to infection. So a severe infection in the bronchial passages are highly likely to progress to the lung, particularly for those with existing comorbidities.

SNG was tested against bronchial infections in their Ásthma trials.

”Two phase-2 studies published earlier, one in 2014 and one in 2018, show that the inhaled SNG001 has a quite favourable effect on the lung function of patients suffering from asthma with symptoms of bronchial viral infections compared to placebo groups.”

https://www.meta.org/papers/the-effect-of-inhaled-ifn--on-worsening-of-asthma/24937476

So if Omicron causes severe infection in bronchial passages SNG001 will have an important role to play.

Prion, It is because it did not work on the vaccinated group. It's all in the data.

Does anyone seriously think the Pfizer pill is going to have more of an influence on the current pandemic than the numerous vaccinations that are already currently approved, have been for 12 months, and yet we are on the verge of another lockdown. It's another useful addition to the armoury, but seriously it will not significantly reduce numbers of people being hospitalised due to the many limitations of it's use and the biggest one for me is this. You need to take a HIV pill to make it work.

Do you really think all these people who won't currently take the vaccine are now going to take a HIV drug. No chance. Soon as they hear HIV they will run for the hills.

Alpha, Omicron patients are still ending up in hospital with covid related pneumonia in South Africa. We will know exactly what is happening in the UK in about 2 weeks time.

There’s been news today that the comparator has lost efficacy against Omicron.

https://www.dailymail.co.uk/health/article-10309179/Eli-Lilly-Regeneron-monoclonal-antibody-Covid-treatments-not-effective-against-Omicron.html

Zero chance of an update pre-results. The company will not pre-empt the regulators response to the data and a manufacturing update would be doing this. I would expect however that detail on manufacturing and availability of the drug would come alongside the data readout if it is good.

RM has made it clear that manufacturing is in place and commercial batches are being produced. There have been indications very recently that the manufacturing capabilities have been expanded.

Once the data readout comes then all will become very clear very quickly.

"- if not then I don't believe you, and neither does the market looking at the SP today lol"

You just proved yourself as a troll with that statement and credibility completely lost IMO.

AiM market is a joke. Time to move to a market where a proper valuation will be applied.

Brilliant news today. Just need the market to wake up to this now!

Ndn, They have already rns'd that data analysis starts tomorrow. They have also never rns'd that on any other trial so don't get your hopes up.

From Nov 11....."Once the final patients have completed the initial 35-day trial period, quality assurance and statistical analysis will be completed."

9pm.

It wasn’t necessarily what he said, although it was a great interview, it was the timing of it .........

Barry, SNG will not licence out the covid treatment. They may do so when it comes to asthma/COPD. They have the suppliers of drug and nebulisers and have already notified shareholders that they have contracted out distribution and in market support.

They are going alone for covid.

Rcdm,

You do realise that Pfizer are projecting $15-20 Billion in revenue from their antiviral pill in 2022.

Anyone selling at £7 will be selling themselves short IMO.

GF, In auction

Doc, I expect that SNG have seen the A2 data. There is provision in the Activ2 protocol for the data to be shared with the the company.

The follow up with RM later this week will be very interesting.